TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03782116

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous electrical stimulation (Elitone)
Description: Transcutaneous perineal area electrical stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation (Elitone)
Description: Transcutaneous perineal area electrical stimulation
Study: NCT03478202

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GOLO RELEASE
Description: GOLO RELEASE plus Diet
Study: NCT01998529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Starting dose of hyperthermic cisplatin 120 mg/m2. Perfusion continued for 60 minutes after adding the cisplatin at a target temperature of 41 C (+0.5 C).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amifostine
Description: Amifostine administered intravenously over 15 minutes beginning 30 minutes (+ 15 minutes) after the cisplatin perfusion.
Study: NCT00967668

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Small change approach to improve physical activity and diet
Description: The Aspire to Lifelong Health (ASPIRE) initial treatment program draws on the strengths of traditional lifestyle change and non-dieting weight loss approaches. ASPIRE incorporates CBT elements, problem-solving therapy, and the small change approach from behavioral choice therapy. For the first week in the program, participants use a food diary to track caloric intake and a pedometer to log their daily physical activity (step counts). Baseline information provides a starting point for participants and their Lifestyle Coach to set one small, but potentially permanent, change in daily food choices and physical activity to promote a caloric deficit. Small changes are cumulative over the weeks and the participant makes their own goals within the context of their own lifestyle.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Small change approach to improve physical activity and diet
Description: The Aspire to Lifelong Health (ASPIRE) initial treatment program draws on the strengths of traditional lifestyle change and non-dieting weight loss approaches. ASPIRE incorporates CBT elements, problem-solving therapy, and the small change approach from behavioral choice therapy. For the first week in the program, participants use a food diary to track caloric intake and a pedometer to log their daily physical activity (step counts). Baseline information provides a starting point for participants and their Lifestyle Coach to set one small, but potentially permanent, change in daily food choices and physical activity to promote a caloric deficit. Small changes are cumulative over the weeks and the participant makes their own goals within the context of their own lifestyle.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MOVE! Usual Care
Description: The MOVE! program offers a stepped-care framework of increasingly intensive treatment. A combination of Level 1 (self-management support) and Level 2 (group sessions and/or individual specialty consultation) will be offered to participants as part of usual care.
Study: NCT03773991

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung MRI
Description: Proton Lung Magnetic Resonance Imaging
Study: NCT04036513

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MINST
Description: For reducing the need of surgical treatment in patients with chronic periodontal disease, we will use specifically designed Hu-Friedy curettes mini five, micro mini five and after five together with piezoelectric device with thin and delicate tips that produce less periodontal trauma than usual Gracey curettes.
Study: NCT02314156

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03839225

Intervention type: OTHER
Group type: OTHER
Intervention: Community intervention
Description: Community intervention will be built depending on contextual factors and will contain the following elements:~* Cross-sector intervention, including sectors to define the intervention as primary health care services, education services (language, knowledge to prevent health problems and resilience strategies), family welfare units, Integral Care and Reparation Unit for Victims (UARIV), Ministry of Labour, national and international social support network, among others.~* The leader will be chosen by the community, with the capabilities to coordinate the community-based network.~* Mental health providers at the local level, who must develop psychosocial and mental diagnoses and interventions, based on experience and evidence, respectively. This team will include psychiatry, psychologists (one an expert in clinical psychology) and a community team involved in the implementation of mental interventions.
Study: NCT02422693

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aquatic Exercises
Description: Exercises performed in the water.
Study: NCT03204708

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iv analgesia
Description: patients were given 100 ml of tramadol 30 minutes before extubation
Study: NCT02422693

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aquatic Exercises
Description: Exercises performed in the water.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Deep-water running
Description: It is a non-impact form of running executed in place in (higher than 2 meters) the water wearing a flotation belt. Heart rate is controlled by heart rate watch
Study: NCT04036513

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional SRP
Description: Scaling and root planing with conventional instruments.
Study: NCT02000219

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oxalobacter formigenes
Description: The dose will be (not less than) NLT ≥1E+09 colony forming units (CFU) twice daily. The dose (an enteric-coated capsule) will be administered orally with breakfast and dinner.
Study: NCT01595308

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pomegranate juice
Description: Pomegranate juice
Study: NCT03773991

Intervention type: DIAGNOSTIC_TEST
Intervention: Sodium MRI
Description: Sodium Soft Tissue Magnetic Resonance Imaging

Intervention type: DIAGNOSTIC_TEST
Intervention: Chest CT
Description: High-resolution Quantitative Chest CT

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Transthoracic 2D Speckle-Tracking Echocardiography

Intervention type: DIAGNOSTIC_TEST
Intervention: Fractional Exhaled Nitric Oxide
Description: Fractional Exhaled Nitric Oxide testing

Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary Function Tests
Description: Spirometry and Plethysmography

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Sampling
Description: Blood testing for: standard-of-care, inflammatory biomarkers, uremic toxins
Study: NCT01207609

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Gastric Plication
Description: The procedure is performed laparoscopic. The greater curvature of the stomach is separated from the greater omentum using a harmonic scalpel starting approximately 3-5 cm from the pylorus and ending at the angle of His. As needed, adhesions to the posterior surface of the stomach may be transected. At least two rows stitches will be placed laparoscopically about the greater curvature of the stomach starting at or near the angle of His and ending in the antrum. A calibration tube or endoscope will be used to maintain a lumen during the procedure, ensuring one exists after the procedure.
Study: NCT01309997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given PO
Study: NCT03773991

Intervention type: DIAGNOSTIC_TEST
Intervention: Six-Minute Walk Test
Description: Six-Minute Walk Test

Intervention type: DIAGNOSTIC_TEST
Intervention: Dyspnea Questionnaires
Description: Modified Medical Research Council; University of California, San Diego Shortness of Breath Questionnaire; Borg Scale
Study: NCT01309997

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study: NCT02807389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC Fistula Plug
Description: Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cell.
Study: NCT00779714

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DTIC (dacarbazine)
Description: 1000 mg/m2, d1 every 21 days
Study: NCT02860741

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REJOICE
Description: Small groups led by lay leaders undergo an 8-session faith-based behavioral activation protocol that provides individuals with education about: identifying depressive symptoms, identifying pleasurable activities, scheduling pleasurable activities, and identifying and addressing avoidant behaviors that act as barriers to completing pleasurable activities

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Churches in the control arm will receive an educational materials about identifying depressive symptoms and self-management options for addressing depressive symptoms.
Study: NCT00879333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus was formulated as tablets of 5 mg strength. In both treatment arms, the study drug was given by continuous oral daily dosing of 10 mg (2 tablets x 5 mg) each morning.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Everolimus placebo
Description: Placebo was formulated to be indistinguishable from the everolimus tablets, also formulated as tablets of 5 mg strength. In both treatment arms, the study drug was given by continuous oral daily dosing of 10 mg (2 tablets x 5 mg) each morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Best Supportive Care (BSC)
Description: Best supportive care is defined as care in accordance with the local practice of an individual institution or center, specifically excluding anti-cancer treatments.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Best Supportive Care (BSC)
Description: Best supportive care is defined as care in accordance with the local practice of an individual institution or center, specifically excluding anti-cancer treatments.
Study: NCT00779714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel + cisplatin
Description: paclitaxel 200 mg/m2 cisplatin 50 mg/m2 d1 every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: treosulfan + cytarabine
Description: treosulfan 2500 mg/m2, d2 cytarabine 100 mg/m2, d1-3 every 21 days
Study: NCT01685281

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metadoxine (MG01CI)
Description: MG01CI is an orally administered extended release formulation of metadoxine. Doses: 1400 mg and 700 mg and Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metadoxine (MG01CI)
Description: MG01CI is an orally administered extended release formulation of metadoxine. Doses: 1400 mg and 700 mg and Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets will be similar in appearance (color and size) to the investigational product
Study: NCT02672033

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo accelerated hypofractionated IMRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo accelerated hypofractionated IMRT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo pleurectomy/decortication
Study: NCT03919721

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Applied Behavioral Analysis
Description: Children are receiving Applied Behavioral Analysis therapy to treat their autism. Therapy is comprised of 15-20 discrete programs that are intended to shape specific behaviors. Tutors collect data on child's performance towards goals. For each child, some of the programs will be tracked with paper data collection methods, others will use electronic data collection. This study is to test the usefulness of the electronic data collection system to replace paper in existing interventions.
Study: NCT03936023

Intervention type: DRUG
Intervention: Saxagliptin
Description: Saxagliptin dispensing claim is the exposure

Intervention type: DRUG
Intervention: Sulfonylurea
Description: 2nd generation sulfonylurea dispensing claim is used as the reference
Study: NCT00873782

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Retrograde high pressure transvenous perfusion with normal saline
Description: Dose escalation of saline volume, infusion rate, and tourniquet pressure, as determined in a stepwise manner and by careful monitoring
Study: NCT03500549

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegcetacoplan
Description: Complement (C3) Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegcetacoplan
Description: Complement (C3) Inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Soliris
Description: Complement (C5) Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soliris
Description: Complement (C5) Inhibitor
Study: NCT04063865

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Tacrolimus (FK / Prograf) titrated to a goal trough of 6 - 8 ng/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus monotherapy - target trough levels 4 - 8 ng/ml as maintenance immunosuppression
Study: NCT04031924

Intervention type: OTHER
Intervention: Assessment of: 1. Functional Capacity 2. Physical Fitness 3. Physical Activity Level 4. Balance 5. Kinesiophobia 6. Psychological Status 7. Fatigue Severity
Description: All liver transplantation patients who underwent transplant at least one year ago and healthy subjects were evaluated the first day they came.

Intervention type: OTHER
Intervention: Assessment of: 1. Functional Capacity 2. Physical Fitness 3. Physical Activity Level 4. Balance 5. Kinesiophobia 6. Psychological Status 7. Fatigue Severity
Description: All liver transplantation patients who underwent transplant at least one year ago and healthy subjects were evaluated the first day they came.
Study: NCT04331028

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shockwave therapy
Description: A shockwave therapy device will be applied in the alveolar socket area of a maxillary tooth, 2 weeks after tooth extraction was performed.
Study: NCT01892241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys(Roche)
Description: 180µg of peginterferon alfa-2a (Pegasys,Roche) once weekly for 48 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: continual entecavir therapy(0.5 mg orally once daily)
Study: NCT02702167

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-frequency rTMS
Description: 10 Hz active stimulation, once daily

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-frequency rTMS
Description: 1 Hz active stimulation, once daily
Study: NCT00381485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol (MF/F) combination
Description: MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 12 weeks
Study: NCT02702167

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: Sham stimulation, once daily
Study: NCT02579863

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: oral capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: oral tablets
Study: NCT01060124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl D-trans
Description: Fentanyl D-trans will be applied as transdermal patch releasing drug at the rate of 12.5 microgram per hour (mcg/hr) for 3 days with a dose ranging from 12 mcg/hr to 50 mcg/hr.
Study: NCT00367705

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: VSL#3®
Description: 1-2 sachets/day per os, 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1-2 sachets/day per os, 6 months
Study: NCT00268476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Study: NCT01685450

Intervention type: DEVICE
Group type: OTHER
Intervention: Echodia® hand-held equipment
Study: NCT01442428

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone: 4 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone: 4 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin: 80 mg once daily (equivalent to 30mg ± 10mg with rifamycin co-administration in this TB population)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin: 80 mg once daily (equivalent to 30mg ± 10mg with rifamycin co-administration in this TB population)
Study: NCT00268476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT
Study: NCT00381485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol (MF/F) combination
Description: MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 12 weeks
Study: NCT00268476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Study: NCT01442428

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Naproxen: 250 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Naproxen: 250 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Atorvastatin placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Atorvastatin placebo
Study: NCT04430478

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Volume flow guided angioplasty
Description: Volume flow measurements using DUS will be obtained at the end of each balloon dilation, at 24 hours, 6 months, and one year after index procedure.
Study: NCT02332954

Intervention type: DRUG
Group type: OTHER
Intervention: vortioxetine
Description: The starting and recommended dose of vortioxetine is 10 mg once daily; film-coated 10 mg tablets for oral use once daily for 52 weeks.Depending on individual patient response, the dose may be increased to a maximum of 20 mg daily.

Intervention type: DRUG
Group type: OTHER
Intervention: vortioxetine
Description: The starting and recommended dose of vortioxetine is 10 mg once daily; film-coated 10 mg tablets for oral use once daily for 52 weeks.Depending on individual patient response, the dose may be increased to a maximum of 20 mg daily.
Study: NCT00405444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: The dose of fentanyl that each child will receive will be 2 mcg/kg based on the child's weight. The medication will be administered 10 minutes prior to the procedure and will be dropped into the unoccluded nares over 1-2 seconds.
Study: NCT03788200

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bracing
Description: Treatment arm #1 (8 weeks of post-injury bracing with rigid cervical collar): Participants randomized to this treatment arm will be treated with 8 weeks in a rigid cervical collar.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: posterior C1-C2 instrumented fusion
Description: Treatment arm #2 (posterior C1-2 instrumented fusion): Participants randomized to this treatment arm will undergo posterior C1-2 instrumented fusion with either local bone grafting or autologous iliac crest bone grafting with or without allograft bone grafting. Bone grafting decision will be made by the treating surgeon. All remaining decisions surrounding medical and surgical care will be made by the attending spine surgeon involved in each case.
Study: NCT00405444

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile water
Description: The dose of sterile water that each child will receive will be 2 mcg/kg based on the child's weight. It will be administered 10 minutes prior to the procedure and will be dropped into the unoccluded nares over 1-2 seconds.
Study: NCT00381485

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone furoate MDI (MF MDI)
Description: MF 400 mcg via metered dose inhaler twice daily for 12 weeks
Study: NCT03478527

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vivomixx® powder
Description: Participants will take in a daily dose of 4.4g for 28 consecutive days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo powder
Description: Participants will take in a daily dose of 4.4g for 28 consecutive days